Publications by authors named "A Azbekyan"
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
Suzana Margareth Lobo Gaétan Plantefève Girish Nair Adilson Joaquim Cavalcante Nara Franzin de Moraes Anait Azbekyan
EClinicalMedicine
February 2024
Article Synopsis
- The study examined whether Mas-receptor activation by BIO101 could help balance the Renin-Angiotensin System and reduce severe respiratory issues in hospitalized COVID-19 patients.
- It was a double-blind, randomized trial involving 238 participants, with findings showing a 11.4% lower rate of respiratory failure or early death in the BIO101 group compared to placebo.
- Results suggest BIO101 may reduce the risk of severe outcomes in COVID-19 patients, although further research is needed due to the low sample size.
Objectives: As of December, 1, 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected people are asymptomatic or experience moderate symptoms and recover without medical intervention. However, older people and those with comorbid hypertension, diabetes, obesity, or heart disease are at higher risk of mortality.
View Article and Find Full Text PDF